<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; out</title>
	<atom:link href="http://www.tapanray.in/tag/out/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Acid Test For Excellence in Crisis Leadership</title>
		<link>http://www.tapanray.in/acid-test-for-excellence-in-crisis-leadership/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=acid-test-for-excellence-in-crisis-leadership</link>
		<comments>http://www.tapanray.in/acid-test-for-excellence-in-crisis-leadership/#comments</comments>
		<pubDate>Mon, 13 Apr 2020 00:07:29 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[21 day]]></category>
		<category><![CDATA[Acid]]></category>
		<category><![CDATA[China]]></category>
		<category><![CDATA[Coronavirus]]></category>
		<category><![CDATA[Country]]></category>
		<category><![CDATA[Covid19]]></category>
		<category><![CDATA[crisis]]></category>
		<category><![CDATA[economic]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Italy]]></category>
		<category><![CDATA[Juty]]></category>
		<category><![CDATA[leader]]></category>
		<category><![CDATA[leadership]]></category>
		<category><![CDATA[lockdown]]></category>
		<category><![CDATA[management]]></category>
		<category><![CDATA[Mask]]></category>
		<category><![CDATA[out]]></category>
		<category><![CDATA[Outbreak]]></category>
		<category><![CDATA[PPE]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Social]]></category>
		<category><![CDATA[society]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[test]]></category>
		<category><![CDATA[turnaround]]></category>
		<category><![CDATA[United Staes]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9986</guid>
		<description><![CDATA[On April 12, 2020 – in the morning of the day 19 of the national lockdown, India’s total number of Coronavirus positive cases reached 8,504 with 289 deaths. The country&#8217;s trajectory is reportedly  steeper than most Asian peers, such as Singapore, Japan, and Indonesia. &#8230; <a href="http://www.tapanray.in/acid-test-for-excellence-in-crisis-leadership/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/acid-test-for-excellence-in-crisis-leadership/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>With Free Medicines In, Would The New Government Revisit ‘Universal Health Coverage’ Soon?</title>
		<link>http://www.tapanray.in/with-free-medicines-in-would-the-new-government-revisit-universal-health-coverage-soon/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=with-free-medicines-in-would-the-new-government-revisit-universal-health-coverage-soon</link>
		<comments>http://www.tapanray.in/with-free-medicines-in-would-the-new-government-revisit-universal-health-coverage-soon/#comments</comments>
		<pubDate>Mon, 02 Jun 2014 00:00:19 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[CMSS]]></category>
		<category><![CDATA[commission]]></category>
		<category><![CDATA[consulting]]></category>
		<category><![CDATA[Coverage]]></category>
		<category><![CDATA[distribution]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[expenditure]]></category>
		<category><![CDATA[Free]]></category>
		<category><![CDATA[harsh]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[HLEG]]></category>
		<category><![CDATA[Hospital]]></category>
		<category><![CDATA[IMS]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[insurance]]></category>
		<category><![CDATA[IP]]></category>
		<category><![CDATA[Manmohan]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[Obamacare]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[oop]]></category>
		<category><![CDATA[OP]]></category>
		<category><![CDATA[out]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[PHC]]></category>
		<category><![CDATA[PHFI]]></category>
		<category><![CDATA[Planning]]></category>
		<category><![CDATA[pocket]]></category>
		<category><![CDATA[Rajasthan]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Reddy]]></category>
		<category><![CDATA[Singh]]></category>
		<category><![CDATA[Srinath]]></category>
		<category><![CDATA[Tamil Nadu]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[UHC]]></category>
		<category><![CDATA[Universal]]></category>
		<category><![CDATA[Vardhan]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=5462</guid>
		<description><![CDATA[Friday last, the new Union Health Minister Dr. Harsh Vardhan reportedly announced that the his ministry would soon start work on distributing free medicines through public hospitals across the country. For this purpose the Minister would soon call a meeting of the &#8230; <a href="http://www.tapanray.in/with-free-medicines-in-would-the-new-government-revisit-universal-health-coverage-soon/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/with-free-medicines-in-would-the-new-government-revisit-universal-health-coverage-soon/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>For Affordable Healthcare: Synergize Resources Through PPP Models</title>
		<link>http://www.tapanray.in/for-affordable-healthcare-synergize-resources-through-ppp-models/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=for-affordable-healthcare-synergize-resources-through-ppp-models</link>
		<comments>http://www.tapanray.in/for-affordable-healthcare-synergize-resources-through-ppp-models/#comments</comments>
		<pubDate>Mon, 24 Feb 2014 00:00:03 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2012]]></category>
		<category><![CDATA[affordable]]></category>
		<category><![CDATA[Central]]></category>
		<category><![CDATA[CMSS]]></category>
		<category><![CDATA[consulting]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[Expenses]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[HLEG]]></category>
		<category><![CDATA[IMS]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[infrastructure]]></category>
		<category><![CDATA[Medical]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[mission]]></category>
		<category><![CDATA[Models]]></category>
		<category><![CDATA[National]]></category>
		<category><![CDATA[NGO]]></category>
		<category><![CDATA[NHM]]></category>
		<category><![CDATA[NRHM]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[oop]]></category>
		<category><![CDATA[out]]></category>
		<category><![CDATA[Partnership]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[pocket]]></category>
		<category><![CDATA[PPP]]></category>
		<category><![CDATA[private]]></category>
		<category><![CDATA[public]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[resources]]></category>
		<category><![CDATA[rural]]></category>
		<category><![CDATA[services]]></category>
		<category><![CDATA[society]]></category>
		<category><![CDATA[synergize]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[UHC]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=4702</guid>
		<description><![CDATA[According to a 2012 study of IMS Consulting, the key factor of significantly high &#8216;Out of Pocket (OOP)&#8217; expenditure on healthcare in India is that people are pushed into seeking costlier private care services due to imbalanced infrastructure of healthcare workers, &#8230; <a href="http://www.tapanray.in/for-affordable-healthcare-synergize-resources-through-ppp-models/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/for-affordable-healthcare-synergize-resources-through-ppp-models/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Humongous Pharma Corruption: China Ups The Ante&#8230;and India?</title>
		<link>http://www.tapanray.in/humongous-pharma-corruption-china-ups-the-ante-and-india/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=humongous-pharma-corruption-china-ups-the-ante-and-india</link>
		<comments>http://www.tapanray.in/humongous-pharma-corruption-china-ups-the-ante-and-india/#comments</comments>
		<pubDate>Mon, 23 Sep 2013 00:00:26 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Alcon]]></category>
		<category><![CDATA[allegations]]></category>
		<category><![CDATA[Apco]]></category>
		<category><![CDATA[Bayer]]></category>
		<category><![CDATA[behind]]></category>
		<category><![CDATA[benefits]]></category>
		<category><![CDATA[biopharmaceuticals]]></category>
		<category><![CDATA[bribers]]></category>
		<category><![CDATA[Business]]></category>
		<category><![CDATA[chases]]></category>
		<category><![CDATA[China]]></category>
		<category><![CDATA[companies]]></category>
		<category><![CDATA[conducts]]></category>
		<category><![CDATA[Corruption]]></category>
		<category><![CDATA[Cost]]></category>
		<category><![CDATA[crack]]></category>
		<category><![CDATA[down]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[EliLilly]]></category>
		<category><![CDATA[ethical]]></category>
		<category><![CDATA[expenditure]]></category>
		<category><![CDATA[fall]]></category>
		<category><![CDATA[far]]></category>
		<category><![CDATA[FCPA]]></category>
		<category><![CDATA[Food]]></category>
		<category><![CDATA[Gan]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[humongous]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[interest]]></category>
		<category><![CDATA[Lee]]></category>
		<category><![CDATA[Lobby]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[milk]]></category>
		<category><![CDATA[MNC]]></category>
		<category><![CDATA[Novartis]]></category>
		<category><![CDATA[oop]]></category>
		<category><![CDATA[out]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[products]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[reasons]]></category>
		<category><![CDATA[regulators]]></category>
		<category><![CDATA[remain]]></category>
		<category><![CDATA[Sanofi]]></category>
		<category><![CDATA[SG&A]]></category>
		<category><![CDATA[Sino]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[the ante]]></category>
		<category><![CDATA[UHC]]></category>
		<category><![CDATA[Up]]></category>
		<category><![CDATA[Values]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=3696</guid>
		<description><![CDATA[In the &#8216;pharma bribery&#8217; related scandal in China, many postulated that the Chinese Government has cracked down selectively on Multinational Corporations (MNCs) to extend unfair business advantages for its local players. Media reports of September 2013 indicate that in all &#8230; <a href="http://www.tapanray.in/humongous-pharma-corruption-china-ups-the-ante-and-india/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/humongous-pharma-corruption-china-ups-the-ante-and-india/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Does the Landmark Glivec Judgment Discourage Innovation in India?</title>
		<link>http://www.tapanray.in/does-the-landmark-glivec-judgment-discourage-innovation-in-india/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=does-the-landmark-glivec-judgment-discourage-innovation-in-india</link>
		<comments>http://www.tapanray.in/does-the-landmark-glivec-judgment-discourage-innovation-in-india/#comments</comments>
		<pubDate>Mon, 08 Apr 2013 00:00:19 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[191]]></category>
		<category><![CDATA[2005]]></category>
		<category><![CDATA[3d]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[Act]]></category>
		<category><![CDATA[AstraZeneca]]></category>
		<category><![CDATA[Case]]></category>
		<category><![CDATA[Challenges]]></category>
		<category><![CDATA[Cipal]]></category>
		<category><![CDATA[commission]]></category>
		<category><![CDATA[Court]]></category>
		<category><![CDATA[Delhi]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[efficacy]]></category>
		<category><![CDATA[gefitinib. Roche]]></category>
		<category><![CDATA[Glenmark]]></category>
		<category><![CDATA[Glivec]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[highcourt]]></category>
		<category><![CDATA[incremental]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[innovative]]></category>
		<category><![CDATA[Innovators]]></category>
		<category><![CDATA[interpretation]]></category>
		<category><![CDATA[IPA]]></category>
		<category><![CDATA[IPO]]></category>
		<category><![CDATA[IPR]]></category>
		<category><![CDATA[Janumet]]></category>
		<category><![CDATA[Januvia]]></category>
		<category><![CDATA[Judgment]]></category>
		<category><![CDATA[knowledge]]></category>
		<category><![CDATA[landmark]]></category>
		<category><![CDATA[medicines. imatinib]]></category>
		<category><![CDATA[mesylate]]></category>
		<category><![CDATA[MSD]]></category>
		<category><![CDATA[Natco]]></category>
		<category><![CDATA[National]]></category>
		<category><![CDATA[Novartis]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[organization]]></category>
		<category><![CDATA[out]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[patentability]]></category>
		<category><![CDATA[pegasys]]></category>
		<category><![CDATA[Pfizer]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[revocation]]></category>
		<category><![CDATA[section]]></category>
		<category><![CDATA[Socioeconomic]]></category>
		<category><![CDATA[step]]></category>
		<category><![CDATA[stutent]]></category>
		<category><![CDATA[Supreme]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[therapeutic]]></category>
		<category><![CDATA[time]]></category>
		<category><![CDATA[TRIPS]]></category>
		<category><![CDATA[WHO]]></category>
		<category><![CDATA[with]]></category>
		<category><![CDATA[wockhardt]]></category>
		<category><![CDATA[World]]></category>
		<category><![CDATA[Zita]]></category>
		<category><![CDATA[Zita-Met]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=2150</guid>
		<description><![CDATA[No, I do not think so. The 112 pages well articulated judgment of the Supreme Court of India delivered on April 1, 2013, does not even remotely discourage innovation in India, including much talked about ‘incremental innovation’. This landmark judgment &#8230; <a href="http://www.tapanray.in/does-the-landmark-glivec-judgment-discourage-innovation-in-india/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/does-the-landmark-glivec-judgment-discourage-innovation-in-india/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Dissapointing: No proposal of &#8216;Healthcare Reform&#8217; in the Union Budget of India for 2011-12: China rolled it out in 2009.</title>
		<link>http://www.tapanray.in/dissapointing-no-proposal-of-healthcare-reform-in-the-union-budget-of-india-for-2011-12-china-rolled-it-out-in-2009/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=dissapointing-no-proposal-of-healthcare-reform-in-the-union-budget-of-india-for-2011-12-china-rolled-it-out-in-2009</link>
		<comments>http://www.tapanray.in/dissapointing-no-proposal-of-healthcare-reform-in-the-union-budget-of-india-for-2011-12-china-rolled-it-out-in-2009/#comments</comments>
		<pubDate>Mon, 28 Feb 2011 00:30:52 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2009]]></category>
		<category><![CDATA[2011-12]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[adequate]]></category>
		<category><![CDATA[Affordability]]></category>
		<category><![CDATA[Budget]]></category>
		<category><![CDATA[China]]></category>
		<category><![CDATA[delivery]]></category>
		<category><![CDATA[Disappointing]]></category>
		<category><![CDATA[expenditure]]></category>
		<category><![CDATA[for]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[in]]></category>
		<category><![CDATA[inadequate]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[infrastructure]]></category>
		<category><![CDATA[it]]></category>
		<category><![CDATA[No]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[of pocket]]></category>
		<category><![CDATA[oop]]></category>
		<category><![CDATA[out]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[proposal]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Reform]]></category>
		<category><![CDATA[rolled]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[the]]></category>
		<category><![CDATA[Union]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=296</guid>
		<description><![CDATA[January 15, 2011 issue of ‘The Lancet’ in an article titled, “Learning from others” states the following: “Having universal coverage through a public commitment does have costs, including public costs. The proportion of national expenditure on health that is met &#8230; <a href="http://www.tapanray.in/dissapointing-no-proposal-of-healthcare-reform-in-the-union-budget-of-india-for-2011-12-china-rolled-it-out-in-2009/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/dissapointing-no-proposal-of-healthcare-reform-in-the-union-budget-of-india-for-2011-12-china-rolled-it-out-in-2009/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>China has recently unfolded the blueprints of its new healthcare reform measures, when will India do so?</title>
		<link>http://www.tapanray.in/china-has-recently-unfolded-the-blueprints-of-its-new-healthcare-reform-measures-when-will-india-do-so/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=china-has-recently-unfolded-the-blueprints-of-its-new-healthcare-reform-measures-when-will-india-do-so</link>
		<comments>http://www.tapanray.in/china-has-recently-unfolded-the-blueprints-of-its-new-healthcare-reform-measures-when-will-india-do-so/#comments</comments>
		<pubDate>Mon, 14 Sep 2009 01:30:36 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[Affordability]]></category>
		<category><![CDATA[blueprints]]></category>
		<category><![CDATA[China]]></category>
		<category><![CDATA[delivery]]></category>
		<category><![CDATA[do]]></category>
		<category><![CDATA[doctors]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[expenditure]]></category>
		<category><![CDATA[GDP]]></category>
		<category><![CDATA[has]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[hospitals]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[infrastructure]]></category>
		<category><![CDATA[its]]></category>
		<category><![CDATA[measures]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[New]]></category>
		<category><![CDATA[nurses]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[oop]]></category>
		<category><![CDATA[out]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[pocket]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[recently]]></category>
		<category><![CDATA[Reform]]></category>
		<category><![CDATA[so]]></category>
		<category><![CDATA[spend]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[the]]></category>
		<category><![CDATA[unfolded]]></category>
		<category><![CDATA[when]]></category>
		<category><![CDATA[Will]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=780</guid>
		<description><![CDATA[Early April, 2009, China, a country with 1.3 billion people, unfolded a plan for a new healthcare reform process for the next decade to provide safe, effective, convenient and affordable healthcare services to all its citizens. A budgetary allocation of &#8230; <a href="http://www.tapanray.in/china-has-recently-unfolded-the-blueprints-of-its-new-healthcare-reform-measures-when-will-india-do-so/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/china-has-recently-unfolded-the-blueprints-of-its-new-healthcare-reform-measures-when-will-india-do-so/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
